Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C12H16F3N
Monoisotopic mass
231.123484132
InChI
InChI=1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3/t9-/m0/s1
InChI Key
InChIKey=DBGIVFWFUFKIQN-VIFPVBQESA-N
IUPAC Name
ethyl[(2S)-1-[3-(trifluoromethyl)phenyl]propan-2-yl]amine
Traditional IUPAC Name
(+)-fenfluramine
SMILES
CCN[C@@H](C)CC1=CC=CC(=C1)C(F)(F)F
pKa (Strongest Basic)
10.22
Refractivity
59.2 m3·mol-1
Dược Lực Học :
Used to treat diabetes and obesity, Dexfenfluramine decreases caloric intake by increasing serotonin levels in the brain’s synapses. Dexfenfluramine acts as a serotonin reuptake inhibitor. It also causes release of serotonin from the synaptosomes.
Cơ Chế Tác Dụng :
Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. It was for some years in the mid-1990s approved by the United States Food and Drug Administration for the purposes of weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn.
Dexfenfluramine binds to the serotonin reuptake pump. This causes inhbition of serotonin reuptake. The increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates.
Dược Động Học :
▧ Absorption :
Well-absorbed from the gastrointestinal tract.
▧ Protein binding :
36%
▧ Half Life :
17-20 hours
Độc Tính :
Symptoms of overdose include respiratory failure and cardiac arrest leading to death.
Chỉ Định :
For the management of obesity including weight loss and maintenance of weight loss in patients on a reduced calorie diet
Tương Tác Thuốc :
-
Acetophenazine
Decreased anorexic effect, may increase psychotic symptoms
-
Alimemazine
Decreased anorexic effect, may increase psychotic symptoms
-
Chlorpromazine
Decreased anorexic effect, may increase psychotic symptoms.
-
Ethopropazine
Decreased anorexic effect, may increase psychotic symptoms
-
Fluoxetine
Risk of serotoninergic syndrome
-
Fluphenazine
Decreased anorexic effect, may increase psychotic symptoms
-
Fluvoxamine
Risk of serotoninergic syndrome
-
Guanethidine
Dexfenfluramine may decrease the effect of guanethidine.
-
Insulin Aspart
Fenfluramine increases the effect of insulin
-
Insulin Detemir
Fenfluramine increases the effect of insulin
-
Insulin Glulisine
Fenfluramine increases the effect of insulin
-
Isocarboxazid
Risk of hypertensive crisis.
-
Mesoridazine
Decreased anorexic effect, may increase psychotic symptoms
-
Methdilazine
Decreased anorexic effect, may increase psychotic symptoms
-
Methotrimeprazine
Decreased anorexic effect, may increase psychotic symptoms
-
Paroxetine
Risk of serotoninergic syndrome
-
Perphenazine
Decreased anorexic effect, may increase psychotic symptoms
-
Phenelzine
Possible hypertensive crisis
-
Prochlorperazine
Decreased anorexic effect, may increase psychotic symptoms.
-
Promazine
Decreased anorexic effect, may increase psychotic symptoms
-
Promethazine
Decreased anorexic effect, may increase pyschotic symptoms.
-
Propericiazine
Decreased anorexic effect, may increase psychotic symptoms.
-
Propiomazine
Decreased anorexic effect, may increase psychotic symptoms
-
Rasagiline
Possible hypertensive crisis
-
Thiethylperazine
Decreased anorexic effect, may increase psychotic symptoms
-
Thioridazine
Decreased anorexic effect, may increase psychotic symptoms
-
Tranylcypromine
Possible hypertensive crisis
-
Trifluoperazine
Decreased anorexic effect, may increase psychotic symptoms
-
Triflupromazine
Decreased anorexic effect, may increase psychotic symptoms
-
Venlafaxine
Risk of serotoninergic syndrome
Liều Lượng & Cách Dùng :
Capsule - Oral